FAVOINO, ELVIRA
 Distribuzione geografica
Continente #
NA - Nord America 3.159
EU - Europa 771
AS - Asia 255
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 4.187
Nazione #
US - Stati Uniti d'America 3.157
IT - Italia 271
SE - Svezia 217
CN - Cina 212
UA - Ucraina 74
DE - Germania 59
FI - Finlandia 55
GB - Regno Unito 42
FR - Francia 27
IN - India 22
VN - Vietnam 14
BE - Belgio 12
IE - Irlanda 6
NL - Olanda 4
ID - Indonesia 2
SG - Singapore 2
AL - Albania 1
AZ - Azerbaigian 1
BZ - Belize 1
CL - Cile 1
CR - Costa Rica 1
EU - Europa 1
GR - Grecia 1
HR - Croazia 1
IM - Isola di Man 1
JP - Giappone 1
TR - Turchia 1
Totale 4.187
Città #
Fairfield 421
Chandler 315
Woodbridge 263
Houston 246
Ashburn 240
Jacksonville 206
Nyköping 192
Ann Arbor 189
Cambridge 184
Seattle 178
Bari 176
Wilmington 166
Nanjing 72
Roxbury 63
Lawrence 62
Beijing 61
Des Moines 42
Princeton 36
Inglewood 34
New York 31
Boardman 23
Dearborn 22
Pune 21
Shenyang 19
Noicattaro 17
San Diego 16
Brooklyn 15
Dong Ket 14
Paris 14
Brussels 12
Nanchang 11
Tianjin 10
Hebei 9
Rome 8
Changsha 6
Dublin 6
Indiana 6
London 6
Los Angeles 6
Auburn Hills 5
Kunming 5
Marseille 5
San Francisco 5
Turin 5
Falls Church 4
Kilburn 4
Washington 4
West Jordan 4
Hefei 3
Jiaxing 3
Redmond 3
Redwood City 3
Acquaviva Picena 2
Acton 2
Amsterdam 2
Arzano 2
Canosa Di Puglia 2
Catanzaro 2
Haikou 2
Helsinki 2
Jinan 2
Napoli 2
New Bedfont 2
Ningbo 2
Norwalk 2
Singapore 2
Tappahannock 2
Aci Catena 1
Atlanta 1
Augusta 1
Bitritto 1
Buffalo 1
Chiswick 1
Dallas 1
Dangriga 1
Douglas 1
Edinburgh 1
Esslingen am Neckar 1
Florence 1
Hounslow 1
Islington 1
Monmouth Junction 1
New Delhi 1
Novara 1
Padova 1
Phoenix 1
Prescot 1
Qingdao 1
San Mateo 1
Sannicandro di Bari 1
Shanghai 1
Taizhou 1
Tirana 1
Tokyo 1
Treviso 1
Wandsworth 1
Windermere 1
Zagreb 1
Éguilles 1
Totale 3.533
Nome #
null 135
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 118
CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading 117
Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis 115
Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin 110
Autoantibodies Recognizing the Amino Terminal 1-17 Segment of CENP-A Display Unique Specificities in Systemic Sclerosis 107
ANTIBODIES TO ENDOPLASMIN AND THEIR USE 105
Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis 100
Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. 99
CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases 98
Methods for treating a tumor using an antibody that specifically binds HMW-MAA 97
The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells 96
AB0695 Subspecificities of Anti-Centromeric-Associated Protein a (CENP-A) Antibodies (AB) Can Identified a Subset of Patients at Higher Risk of Developing Pulmonary Hypertension 93
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease 92
CD20 mimicry by a mAb rituximab-specific linear peptide: A potential tool for active immunotherapy of autoimmune diseases 86
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor 84
Rheumatic disorders as paraneoplastic syndromes 83
CD20: A target antigen for immunotherapy of autoimmune diseases 80
Novel combinatorial therapy for pancreatic adenocarcinoma 80
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? 79
null 77
Effects of Adjuvants for Human Use in Systemic Lupus Erythematosus (Sle)-Prone (Nzb/Nzw) F1 Mice 76
CD20 mimicry by mAb Rituximab-specific linear peptide. A potential tool for active immunotherapy of autoimmune diseases 75
Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes 74
Abstract 4390: Heat shock protein (HSP) Grp94-targeted combinatorial immunotherapy for pancreatic cancer 73
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors 71
Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease 70
Targeting cancer initiating cells in pancreatic adenocarcinoma 68
Response to "Is active acid sphingomyelinase required for the antiproliferative response to rituximab?" [e-letter]. http://bloodjournal.hematologylibrary.org/content/117/13/3695.citation/reply#bloodjournal_el_2268 66
Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: Putative implication of a low anti-carbamylated protein antibodies prevalence 66
Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: Implication for peptide-based active immunotherapy 65
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4 65
CSPG4 in cancer: Multiple roles 64
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence 64
Identification of an antigenic and immunogenic motif expressed by two 7-Mer Rituximab-specific cyclic peptides 61
Anti-carbamylated protein antibodies in patients with systemic sclerosis: an intriguing association with skin involvement 61
Antitumor activity of BRAF inhibitor and IFN×alpha; Combination in BRAF-mutant melanoma 55
Identificazione del peptide che mima l'epitopo localizzato sulla catena pesante HLA-I non associata alla beta 2-microglobulina, riconosciuto dall'anticorpo monoclonale HC-10 54
Beta2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 54
Harnessing host innate immunity may combat acquired resistance to BRAFi 53
SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? 53
EXPRESSION OF THE TRANSCRIPTION FACTOR FORKHEAD BOX E3 (FOXE3) IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH SYSTEMIC SCLEROSIS 52
Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope 52
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count 51
Sars-cov-2 inflammatory syndrome. Clinical features and rationale for immunological treatment 51
Dietary cholesterol supplementation and inhibitory factor 1 serum levels in two dizygotic Smith-Lemli-Opitz syndrome twins: a case report 49
null 48
EXPRESSION OF THE TRANSCRIPTION FACTOR FORKHEAD BOX E3 (FOXE3) IN MONOCYTES FROM PATIENTS WITH SYSTEMIC SCLEROSIS AND CORRELATION WITH THEIR SEROLOGICAL PROFILE 47
Metodo ELISA: dosaggio della catena pesante della molecola HLA non associata alla b2-microglobulina 41
Insight into the specificità of the anti-CD20 monclonal antibody Rituximab. 41
AUTO-ANTIBODIES TO THE AMINO TERMINAL SEGMENT (AMINOACID 1-17) OF CENP-A DISPLAY A UNIQUE SPECIFICITY IN SYSTEMIC SCLEROSIS AND ARE INDEPENDENTLY EXPRESSED FROM THOSE AGAINST CENP-B 41
Poems syndrome with amyloidosis and calchyphylaxis.A case report 40
Peptidi che mimano l'antigene CD20: potenzialità terapeutiche nel lupus eritematoso sistemico 37
Characterization of the specificity of the Human scFv W9 35
Ruolo degli autoanticorpi nelle patologie autoimmuni 33
null 33
Quantitative evaluation of anti-FOXE-3 Ab identifies a subset of anti-CENP positive systemic sclerosis patients who are less prone to develop active disease 31
Phlegmonous abscess associated with etanercept therapy 30
Functional characterization of peptides mimicking the CD20 epitope recognized by Rituximab 28
Raynaud’s phenomenon: from molecular pathogenesis to therapy 28
Two structurally different peptides mimic a CD20 epitope recognized by rituximab 27
Mimotope peptides in the immunization against CD20: a promising approach to the therapy of autoimmune diseases 26
 Peptides highly specific to the variable region of TNF-ALFA-specific references licensed (RL) monoclonal antibodies (MAB), as potential tool to effectively assess similarity between biosimilars and the correspondig RL MAB 25
Generation of linear and cyclic peptides revealed a unique fine specificity of Rituximab and its possible cross-reactivity with an acid sphingomyelinase-like phosphodiesterasem 3B precursor 24
Identification of an antigenic and immunogenic motif expressed by two 7-Mer Rituximab-specific cyclic peptides. Journal of Immunology 23
Chronic-Relapsing cutaneous leukocytoclastic vasculitis in a young patient with reduced EBV-specific T cell response using enzyme-linked immunospot (ELISPOT) assay successfully treated with Valaciclovir 21
Ruolo degli autoanticorpi nelle patologie autoimmuni 19
Circulating Inhibitory Factor 1 levels in adult patients with Prader-Willi syndrome 19
null 18
Novel biomarker for pulmonary vascular disease in systemic sclerosis patients 15
Functional characterization of peptides mimicking the CD-20 epitope recognized by Rituximab 9
Methods for treating a tumor using an antibody that specifically binds grp94 9
Circulating Irisin Levels in Patients with Chronic Plaque Psoriasis. 8
Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity 7
null 7
Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces 4
Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis 4
Impact of belimumab therapy on the quality of life in patients with systemic lupus erythematosus: A cohort study 3
Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study 3
β2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 3
Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma 2
Endothelial cells in tumor microenvironment: insights and perspectives 1
HLA allele prevalence in disease-modifying antirheumatic drugs-responsive enthesitis and/or arthritis not fulfilling ASAS criteria: Comparison with psoriatic and undifferentiated spondyloarthritis 1
Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity 1
Classic pyoderma gangrenosum 1
Totale 4.387
Categoria #
all - tutte 16.879
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.879


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019321 0 0 0 0 0 0 0 0 0 66 127 128
2019/20201.061 173 56 31 92 135 108 98 75 111 54 110 18
2020/2021766 69 21 60 29 116 50 131 83 62 75 36 34
2021/2022523 24 67 6 18 22 34 51 22 32 23 98 126
2022/2023867 124 96 46 75 110 111 29 120 117 9 16 14
2023/2024316 24 54 19 72 21 78 11 21 8 8 0 0
Totale 4.387